Abstract: A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary.
Introduction
In modern breast cancer management, neoadjuvant chemotherapy (NACT) is frequently employed to downstage tumors before surgical intervention. A primary goal of NACT is achieving a pathological complete response (pCR), defined as the total absence of invasive cancer in the breast tissue at the time of surgery.
However, a clinical dilemma persists regarding the management of the axilla (armpit lymph nodes) in patients who were initially node-positive (N1+). Even when the primary breast tumor vanishes, standard practice often involves an Axillary Lymph Node Dissection (ALND). While effective for staging, ALND is invasive and carries a high risk of chronic complications like lymphedema. This study investigates whether the response of the primary tumor can reliably predict nodal clearance, potentially allowing some patients to avoid aggressive axillary surgery.
Methods
This research was conducted as a unicentral retrospective cohort study at the National Cancer Institute in Cairo, Egypt. The researchers analyzed a clinical dataset of 367 breast cancer patients treated between 2013 and 2017.
From this larger pool, the study focused on a subset of 77 patients who met two specific criteria: they were clinically node-positive at presentation and achieved a confirmed pCR in the breast following NACT. All patients underwent a full axillary clearance regardless of their clinical response, providing a "ground truth" pathological assessment of the lymph nodes. The researchers then correlated nodal status with biological markers including hormone receptor (HR) status, HER2 status, tumor grade, and histological type.
Results and Analysis
The study found a strong correlation between the primary tumor's response and the status of the axillary nodes. Of the 77 patients who achieved breast pCR, 62 (80.5%) also achieved nodal pCR (N0), while 15 (19.5%) still harbored residual disease in the nodes (N1).
The Role of Tumor Biology
The data revealed that molecular subtype and tumor grade were far more predictive of nodal clearance than the initial tumor size. Key findings include:
- High Responders: HER2-positive and triple-negative breast cancer (TNBC) subtypes showed the highest rates of combined clearance (91.7% and 78.2%, respectively). Notably, 100% of Grade 3 tumors in this cohort achieved nodal pCR.
- Hormone Receptor Impact: Patients with negative or weak hormone receptor status were significantly more likely to achieve nodal pCR (OR 7.8; p = 0.007) compared to those with strongly positive receptors.
- Resistant Subtypes: Lobular carcinomas (ILC) and strongly ER-positive tumors were less likely to mirror the breast's response in the nodes. As shown in the data, only 50% of ILC patients achieved nodal clearance despite having a clear breast specimen.
Discussion and Clinical Implications
The findings suggest that for specific "high-responder" groups—particularly HER2-positive and ER-negative patients—the achievement of breast pCR is a highly reliable indicator that the axilla has also cleared. In these cases, the traditional ALND may be overtreatment.
Instead, the authors suggest that less invasive staging techniques, such as Targeted Axillary Dissection (TAD) or Sentinel Lymph Node Biopsy (SLNB), could be sufficient to confirm nodal status. This shift could significantly reduce surgical morbidity and improve the quality of life for breast cancer survivors.
Limitations
As a retrospective study with a focused subset of 77 patients, these results require validation through larger prospective trials. Additionally, the initial nodal staging relied on ultrasound; while reliable, it is not the gold standard of biopsy. Future research should focus on implementing TAD in prospective cohorts to ensure that skipping ALND does not compromise oncological safety.
Summary updated